Home LiteratureArticle Details
PMID: 10826883 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Probing hydrogen bonds in the antibody-bound HIV-1 gp120 V3 loop by solid state NMR REDOR measurements.

Journal of biomolecular NMR ·Vol. 16 ·No. 4 ·2000-04-00 ·Pages 313-27

Balbach JJ, Yang J, Weliky DP, Steinbach PJ, Tugarinov V, Anglister J, Tycko R

Abstract

We describe solid state NMR measurements on frozen solutions of the complex of the 24-residue HIV-1 gp120 V3 loop peptide RP135 with the Fab fragment of the anti-gp120 antibody 0.5beta, using rotational echo double resonance (REDOR). In order to probe possible hydrogen bonding between arginine side chains and glycine backbone carbonyls in the region of the conserved Gly-Pro-Gly-Arg (GPGR) motif of the V3 loop, RP135 samples were prepared with 15N labels at the eta nitrogen positions of arginine side chains and 13C labels at glycine carbonyl positions and 13C-detected 13C-15N REDOR measurements were performed on peptide/antibody complexes of these labeled samples. Such hydrogen bonding was previously observed in a crystal structure of the V3 loop peptide/antibody complex RP142/59.1 [Ghiara et al. (1994) Science, 264, 82-85], but is shown by the REDOR measurements to be absent in the RP135/0.5beta complex. These results confirm the antibody-dependent conformational differences in the GPGR motif suggested by previously reported solid state NMR measurements of phi and psi backbone dihedral angles in the RP135/0.53 complex. In addition, we describe REDOR measurements on the helical synthetic peptide MB(i+4)EK in frozen solution that establish our ability to detect 13C-15N dipole-dipole couplings in the distance range appropriate to these hydrogen bonding studies. We also report the results of molecular modeling calculations on the central portion RP135, using a combination of the solid state NMR restraints of Weliky et al. [Nat. Struct. Biol., 6, 141-145, 1999] and the liquid state NMR restraints of Tugarinov et al. (Nat. Struct. Biol., 6, 331-335, 1999]. The dynamics calculations demonstrate the mutual compatibility of the two sets of experimental structural restraints and reduce ambiguities in the solid state NMR restraints that result from symmetry and signal-to-noise considerations.

MeSH Terms
Antigen-Antibody Complex/chemistry Arginine/metabolism Epitopes/chemistry,metabolism Glycine/metabolism HIV Antibodies/chemistry,metabolism HIV Envelope Protein gp120/chemistry,immunology,metabolism Hydrogen Bonding Immunoglobulin Fab Fragments/chemistry,metabolism Models, Molecular Nuclear Magnetic Resonance, Biomolecular/methods Protein Structure, Tertiary Thermodynamics
Chemicals
Antigen-Antibody Complex Epitopes HIV Antibodies HIV Envelope Protein gp120 Immunoglobulin Fab Fragments Arginine Glycine
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Balbach J J
Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0520, USA.
Yang J
Weliky D P
Steinbach P J
Tugarinov V
Anglister J
Tycko R
References (46)
46 references, click to expand
  1. Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF.
    Biochemistry. 1996 Apr 23;35(16):5158-65 PMID: 8611499
  2. NMR study of the peptide present in the principal neutralizing determinant (PND) of HIV-1 envelope glycoprotein gp120.
    J Biochem Biophys Methods. 1997 Mar 27;34(2):83-98 PMID: 9178085
  3. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.
    Science. 1998 Jun 19;280(5371):1949-53 PMID: 9632396
  4. Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs.
    Structure. 1999 Feb 15;7(2):131-42 PMID: 10368281
  5. Preparation and properties of Nalpha-9-fluorenylmethyloxycarbonylamino acids bearing tert.-butyl side chain protection.
    Int J Pept Protein Res. 1980 Jan;15(1):59-66 PMID: 7358458
  6. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy.
    Biochemistry. 1997 Jul 15;36(28):8619-27 PMID: 9214308
  7. Conformational features of a synthetic cyclic peptide corresponding to the complete V3 loop of the RF HIV-1 strain in water and water/trifluoroethanol solutions.
    Eur J Biochem. 1996 Feb 15;236(1):100-8 PMID: 8617252
  8. Crystallization, sequence, and preliminary crystallographic data for an antipeptide Fab 50.1 and peptide complexes with the principal neutralizing determinant of HIV-1 gp120.
    Proteins. 1992 Dec;14(4):499-508 PMID: 1438187
  9. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.
    Cell. 1996 Jun 28;85(7):1135-48 PMID: 8674119
  10. Unusually stable helix formation in short alanine-based peptides.
    Proc Natl Acad Sci U S A. 1989 Jul;86(14):5286-90 PMID: 2748584
  11. Structural comparison of a 15 residue peptide from the V3 loop of HIV-1IIIb and an O-glycosylated analogue.
    FEBS Lett. 1996 Sep 16;393(2-3):280-6 PMID: 8814305
  12. A cis proline turn linking two beta-hairpin strands in the solution structure of an antibody-bound HIV-1IIIB V3 peptide.
    Nat Struct Biol. 1999 Apr;6(4):331-5 PMID: 10201400
  13. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.
    Nature. 1996 Nov 14;384(6605):179-83 PMID: 8906795
  14. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
    Proc Natl Acad Sci U S A. 1988 May;85(9):3198-202 PMID: 2452447
  15. Solution structure of the V3 loop of a Thailand HIV isolate.
    J Biomol Struct Dyn. 1993 Oct;11(2):345-66 PMID: 8286061
  16. Solid-state NMR evidence for an antibody-dependent conformation of the V3 loop of HIV-1 gp120.
    Nat Struct Biol. 1999 Feb;6(2):141-5 PMID: 10048925
  17. Prediction of the secondary structure of HIV-1 gp120.
    Proteins. 1996 May;25(1):1-11 PMID: 8727315
  18. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry.
    J Virol. 1998 Jan;72(1):279-85 PMID: 9420225
  19. Determination of three-dimensional structures of proteins from interproton distance data by hybrid distance geometry-dynamical simulated annealing calculations.
    FEBS Lett. 1988 Mar 14;229(2):317-24 PMID: 3345845
  20. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.
    Science. 1990 Aug 24;249(4971):932-5 PMID: 2392685
  21. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.
    Annu Rev Immunol. 1999;17:657-700 PMID: 10358771
  22. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1.
    Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11518-22 PMID: 7505441
  23. Sampling and efficiency of metric matrix distance geometry: a novel partial metrization algorithm.
    J Biomol NMR. 1992 Jan;2(1):33-56 PMID: 1422145
  24. NMR structure of the principal neutralizing determinant of HIV-1 displayed in filamentous bacteriophage coat protein.
    J Mol Biol. 1997 Mar 7;266(4):649-55 PMID: 9102458
  25. Solution conformation of an immunogenic peptide derived from the principal neutralizing determinant of the HIV-2 envelope glycoprotein gp125.
    Fold Des. 1996;1(2):157-65 PMID: 9079375
  26. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Nature. 1998 Jun 18;393(6686):705-11 PMID: 9641684
  27. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.
    Nature. 1996 Nov 14;384(6605):184-7 PMID: 8906796
  28. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
    Nature. 1998 Jun 18;393(6686):648-59 PMID: 9641677
  29. Patterns of CCR5, CXCR4, and CCR3 usage by envelope glycoproteins from human immunodeficiency virus type 1 primary isolates.
    J Virol. 1998 May;72(5):4485-91 PMID: 9557746
  30. NMR study and comparison of the antigenic properties of a peptide recognized by two HIV-1 neutralizing antibodies.
    J Mol Recognit. 1997 Nov-Dec;10(6):256-61 PMID: 9770649
  31. Raster3D: photorealistic molecular graphics.
    Methods Enzymol. 1997;277:505-24 PMID: 18488322
  32. Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen.
    Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6325-9 PMID: 8327513
  33. Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site.
    J Mol Biol. 1997 Feb 14;266(1):31-9 PMID: 9054968
  34. Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain.
    J Virol. 1991 Jan;65(1):190-4 PMID: 1985197
  35. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.
    Science. 1990 Dec 14;250(4987):1590-3 PMID: 1703322
  36. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.
    J Virol. 1988 Jun;62(6):2107-14 PMID: 2452899
  37. Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization.
    Virology. 1993 Jan;192(1):197-206 PMID: 7685962
  38. Nuclear magnetic resonance analysis of solution conformations in C4-V3 hybrid peptides derived from human immunodeficiency virus (HIV) type 1 gp120: relation to specificity of peptide-induced anti-HIV neutralizing antibodies.
    J Virol. 1999 Jan;73(1):746-50 PMID: 9847381
  39. The principal neutralizing determinant of HIV-1 located in V3 of gp120 forms a 12-residue loop by internal hydrophobic interactions.
    FEBS Lett. 1995 Jul 17;368(2):267-70 PMID: 7543061
  40. Helix stabilization by Glu-...Lys+ salt bridges in short peptides of de novo design.
    Proc Natl Acad Sci U S A. 1987 Dec;84(24):8898-902 PMID: 3122208
  41. Crystal structure of the principal neutralization site of HIV-1.
    Science. 1994 Apr 1;264(5155):82-5 PMID: 7511253
  42. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection.
    Nat Med. 1996 Nov;2(11):1244-7 PMID: 8898753
  43. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1.
    Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9434-8 PMID: 1409653
  44. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding.
    J Exp Med. 1997 Oct 20;186(8):1373-81 PMID: 9334377
  45. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
    Proc Natl Acad Sci U S A. 1989 Sep;86(17):6768-72 PMID: 2771954
  46. Solution conformational preferences of immunogenic peptides derived from the principal neutralizing determinant of the HIV-1 envelope glycoprotein gp120.
    Biochemistry. 1991 Sep 24;30(38):9187-94 PMID: 1892828
Article Info
Journal
Journal of biomolecular NMR
Abbr.
J Biomol NMR
ISSN
0925-2738
Published
2000-04-00
Pages
313-27
Language
English
Region
Netherlands
NLM ID
9110829
Subset
IM
Grants
NIGMS NIH HHS · GM53329 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com